Buscar
Mostrando ítems 1-10 de 23
Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins
(2015-06)
The venom proteome of the monocled cobra, Naja kaouthia, from Thailand, was characterized by RPHPLC,
SDS-PAGE, and MALDI-TOF-TOF analyses, yielding 38 different proteins that were either identified
or assigned to families. ...
Exploration of immunoglobulin transcriptomes from mice immunized with three-finger toxins and phospholipases A2 from the Central American coral snake, Micrurus nigrocinctus
(2017)
Snakebite envenomings represent a neglected public health issue in many parts of the
rural tropical world. Animal-derived antivenoms have existed for more than a hundred
years and are effective in neutralizing snake venom ...
From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy
(2016)
The snake is the symbol of medicine due to its association with Asclepius, the
Greek God of medicine, and so with good reasons. More than 725 species of venomous
snakes have toxins specifically evolved to exert potent ...
Exploring the venom of the forest cobra snake: Toxicovenomics and antivenom profiling of Naja melanoleuca
(2017-01-06)
A toxicovenomic analysis of the venomof the forest cobra, N. melanoleuca,was performed, revealing the presence
of a total of 52 proteins by proteomics analysis. The most abundant proteins belong to the three-finger ...
High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction
(2017-11)
Polyvalent snakebite antivenoms derive their therapeutic success from the ability of their antibodies to
neutralize venom toxins across multiple snake species. This ability results from a production process
involving ...
Discovery and optimization of a broadly-neutralizing human antibody against long-chain α-neurotoxins from snakes
(2023-02-08)
Snakebite envenoming continues to claim many lives across the globe, necessitating the development of improved therapies. To this end, broadly-neutralizing human monoclonal antibodies may possess advantages over current ...
Novel snakebite therapeutics must be tested in appropriate rescue models to robustly assess their preclinical efficacy
(2020)
In the field of antivenom research, development, and manufacture, it is often advised to follow the World Health Organization’s (WHO) guidelines for the production, control, and regulation of snake antivenom immunoglobulins, ...
Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score
(2015-09-15)
For more than 100 years, antivenoms have been produced by traditional methods of immunization of large mammals with mixtures of snake venoms (World Health Organization, 2010 and Gutiérrez et al., 2011). With the introduction ...
Antibody-dependent enhancement of toxicity of myotoxin II from Bothrops asper
(2024)
Improved therapies are needed against snakebite envenoming, which kills and
permanently disables thousands of people each year. Recently developed
neutralizing monoclonal antibodies against several snake toxins have ...
Pitfalls to avoid when using phage display for snake toxins
(2017-02)
Antivenoms against bites and stings from snakes, spiders, and scorpions are associated with immunological side effects and high cost of production, since these therapies are still derived from the serum of hyper-immunized ...